Physician profile
Markesh K Manocha
NPI 1396744181
$62,921.78
in general payments reported to CMS, 2019-2025
30 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $998 · 2021: $3,263 · 2022: $17K · 2023: $9,336 · 2024: $14K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Food and Beverage: $9,570 · Travel and Lodging: $4,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,200.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,385.00 |
| Food and Beverage | $9,570.19 |
| Travel and Lodging | $4,316.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $47,043.39 | 2019-2025 | Cequa |
| Alcon Vision LLC | $3,022.39 | 2019-2025 | Clareon, Hydrus Microstent, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $1,546.95 | 2019-2025 | Veritas Vision System, Tecnis Iol, Tecnis Iol |
| Glaukos Corporation | $1,519.34 | 2021-2024 | Ce-Marked Kxla System, Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| New World Medical,INC. | $1,472.02 | 2019-2025 | Streamline, Clearpath, Ahmed Glaucoma Valve |
| Abbvie INC. | $1,080.33 | 2022-2025 | |
| Rxsight INC | $991.50 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $964.22 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $795.73 | 2019-2022 | |
| Oyster Point Pharma, INC. | $560.36 | 2022-2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $526.40 | 2021-2025 | Acthar |
| Biotissue Holdings INC. | $504.22 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $458.28 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $419.38 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $371.98 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $357.16 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $278.88 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $180.38 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $156.75 | 2020-2022 | |
| Rayner Intraocular Lenses Limited | $144.76 | 2022-2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Dompe US, INC. | $116.50 | 2021-2025 | Oxervate |
| Shire North American Group INC | $94.35 | 2019 | |
| Harrow Eye, LLC | $83.78 | 2024-2025 | Vevye |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Thea Pharma INC. | $62.28 | 2023-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $26.58 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $22.00 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $21.78 | 2025 | Tepezza |
| Omeros Corporation | $17.94 | 2021 | |
| Eyepoint US, INC. | $17.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Markesh Manocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.